A review of erlotinib–an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
R Iyer, A Bharthuar - Expert opinion on pharmacotherapy, 2010 - Taylor & Francis
Importance of the field: The epidermal growth factor receptor (EGFR) is a cell surface
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
A review of erlotinib and its clinical use
PA Tang, MS Tsao, MJ Moore - Expert opinion on pharmacotherapy, 2006 - Taylor & Francis
Erlotinib is an orally available, reversible tyrosine kinase inhibitor of the epidermal growth
factor receptor. Encouraging activity as a single agent and in combination with other …
factor receptor. Encouraging activity as a single agent and in combination with other …
Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer
J Smith - Clinical therapeutics, 2005 - Elsevier
BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …
Erlotinib in non-small-cell lung cancer
C Gridelli, A Rossi, P Maione… - Expert opinion on …, 2007 - Taylor & Francis
Epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth and
differentiation, and is involved in tumour proliferation and survival. EGFR overexpression is …
differentiation, and is involved in tumour proliferation and survival. EGFR overexpression is …
Erlotinib in the treatment of non-small cell lung cancer
ER Brown, FA Shepherd - Expert review of anticancer therapy, 2005 - Taylor & Francis
Inhibition of the epidermal growth factor receptor is one of the most promising novel
therapeutic strategies to be used in the treatment of patients with non-small cell lung cancer …
therapeutic strategies to be used in the treatment of patients with non-small cell lung cancer …
Erlotinib in cancer treatment
MA Bareschino, C Schettino, T Troiani, E Martinelli… - Annals of oncology, 2007 - Elsevier
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK)
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …
Reviewing the safety of erlotinib in non-small cell lung cancer
M Reck, T Mok, J Wolf, D Heigener… - Expert opinion on drug …, 2011 - Taylor & Francis
Importance of the field: Erlotinib, a potent inhibitor of EGFR activity, is approved as a
monotherapy for the treatment of advanced NSCLC and in combination with gemcitabine for …
monotherapy for the treatment of advanced NSCLC and in combination with gemcitabine for …
Erlotinib: a new therapeutic approach for non-small cell lung cancer
P Bonomi - Expert opinion on investigational drugs, 2003 - Taylor & Francis
Although treatment with cytotoxic agents has produced modest survival improvement in
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …